Metabolon, Inc., a Research Triangle Park, N.C.-based health technology company, raised an additional $15 million in funding.
Essex Woodlands, a healthcare growth equity firm, made the investment, which added to an initial $15m investment in August 2016.
The company intends to use the funds to further develop and commercialize its pipeline of precision medicine products employing its proprietary metabolomics technology.
Founded in 2000, Metabolon focuses on the use of metabolomics in precision medicine. Its tool for assessing health is based on proprietary platforms and informatics that deliver biomarker discoveries, innovative diagnostic tests, and partnerships in genomics-based health initiatives.
To date, the company has conducted more than 5,000 independent and collaborative studies, resulting in over 600 peer-reviewed publications.
FinSMEs
06/12/2016